

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
SEVEN PRODUCTS INCLUDING
**“EFBEMALENOGRASTIM ALFA INJECTION (THE THIRD GENERATION LONG-
ACTING G-CSF)” ADDED AND INCLUDED IN THE NATIONAL MEDICAL
INSURANCE CATALOGUE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that seven of the Group’s products, including “Efbemalenograstim alfa Injection (艾貝格司亭 α 注射液)” (marketed as Yilishu (億立舒)), have been successfully added and included in the *National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023)*, which are expected to be important products contributing to the Group’s revenue growth in 2024.

Yilishu is a new generation of long-acting granulocyte colony-stimulating factor (G-CSF) and the world’s first third generation long-acting G-CSF innovative medicine, with innovative upgrades in structure and process as well as three key advantages: better clinical performance, better safety and earlier dosing. In May 2023, Yilishu received marketing approval from the National Medical Products Administration of the PRC for the use in adult patients with non-myeloid malignant tumors to reduce the incidence of infections manifested by febrile neutropenia when receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. In November 2023, Efbemalenograstim alfa Injection received marketing approval from the US Food and Drug Administration (FDA). Currently, the market scale of G-CSF in the PRC is nearly RMB10 billion.

In recent years, the Group has actively responded to national policies and continuously promoted the admission of its products to the National Medical Insurance Catalogue in order to increase the cure rate and drug accessibility for patients. Besides Efbemalenograstim alfa Injection, the Group’s Sitagliptin and Metformin Hydrochloride Sustained-release Tablets (西格列汀二甲雙胍緩釋片), Lubiprostone Soft Capsules (蘆比前列酮軟膠囊), Tedizolid Phosphate Tablets (磷酸特地唑胺片), Tedizolid Phosphate for

Injection (注射用磷酸特地唑胺), Trifluridine and Tipiracil Hydrochloride Tablets (曲氟尿苷替匹嘧啶片) and Calcitriol Oral Solution (骨化三醇口服溶液), a total of 7 drugs, are added and included in the National Medical Insurance Catalogue. In the future, the Group will continue to introduce high-quality and affordable medicines for patients with unmet clinical needs as its orientation, contributing to the improvement of public health level and accessibility of medicines for patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.